Loading…

Precigen IncPGENCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops gene and cell therapies including an approved treatment for recurrent respiratory papillomatosis.

Momentum laggard 16
Mkt cap
$1.53B
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$39.3M
20-day average traded
Fwd P/E
7.3×
forward earnings
ROIC−WACC
+9.6 pp
WACC 9.9%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$4.27
1D-0.5%
1W-9.5%
1M-37.5%
3M-42.6%
6M0.0%
YTD+2.1%
1Y-12.9%
ATR %10.6%
Beta1.68
52w lowhigh52.5% off high

What Precigen does

Develops gene and cell therapies including an approved treatment for recurrent respiratory papillomatosis.

Its first product, Papzimeos, treats recurrent respiratory papillomatosis, a rare condition where wart-like growths block the airways, and is sold to specialist hospitals. Before approval it lived on licensing deals and shares sold to investors. Randal Kirk's Third Security has long been the largest shareholder.

Products and services

  • Papzimeos (RRP treatment)
  • Gene therapy pipeline (cancer, autoimmune)

Customers

  • ENT specialists/hospitals (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Gene and cell therapy

What could go right

  • Papzimeos commercial ramp
  • Pipeline partnership and licensing deals

What could go wrong

  • Cash burn ahead of profitability
  • Rare-disease market size limits

Moat: none (IP / patents, regulatory licence). First mover with an approved rare-disease gene therapy, but a thin, still-loss-making commercial base.

Headquarters: Germantown, Maryland, US · Founded: 1998 · Employees: 160

Named competitors

Precigen at a glance

Size Precigen (PGEN) is a United States Health Care company (Biotechnology) with a market value of $1.53B, the 1960th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.27 on 18 Nov 2026.

Performance Over six months the shares was unchanged, against -12.8% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 2,387.6% over the last twelve months (peer median +25.4%); the operating margin is 21.4% (peer median -5.7%).

Valuation It trades at 7.3× forward earnings against a peer median of 37.0× (cheapest of 9).

Capital Return on invested capital runs 9.6 points above its cost of capital (9.9% WACC).

Short interest Short interest is 12.5% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026PGEN 100Peer median 86
Six months, rebased to 100: Precigen against the median of its 20 peers (local-currency closes).

Precigen financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$157M$9.68M$3.92M$6.22M$26.9M
Revenue growth—+147%-37%-77%—
Gross profit$142M$3.59M-$3.40M-$4.74M$15.8M
EBITDA$38.1M-$103M-$90.2M-$82.3M-$67.4M
Net income$24.4M-$251M-$126M-$95.9M-$66.4M
Free cash flow-$74.3M-$89.8M-$76.8M-$68.5M-$70.0M
Capital expenditure$1.10M$2.00M$8.58M$1.54M$4.92M
Total debt$98.6M$98.3M$5.50M$7.10M$51.4M

Quarterly statements and history in the cockpit →

Precigen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%KLRANRIXKRSA688319VIR087010MSB2637URGNPPGN6887656949688222ALVOANIP600226688105QUREPGEN6-month return →1-month return →
Up and to the right = strong over both horizons. Precigen is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×50×100×2637URGNPPGN688222ALVOANIP688105PGENRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Precigen is the large dot.

Precigen competitors and peer comparison

Head to head with its named competitors (PGEN vs RARE vs PTCT vs NTLA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Precigen PGEN$1.53B0%+2,388%21%7.3×n/a
Ultragenyx Pharmaceutical RARE$1.81B-24%+16%-64%9.6×n/a
PTC Therapeutics PTCT$5.03B-15%-35%22%31.2×6.6%
Intellia Therapeutics NTLA$1.37B-20%-8%-821%n/an/a

How Precigen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Precigen against its 20 peers (data as of 18 Nov 2026)
MeasurePGENPeer medianRank in peer set
1-month return-37.5%-10.9%2nd lowest of 21
6-month return0.0%-12.8%7th highest of 20
Distance from 52-week high-52.5%-44.5%6th lowest of 21
Revenue growth (TTM)+2,387.6%+25.4%highest of 19
Operating margin21.4%-5.7%4th highest of 19
Forward P/E7.3×37.0×cheapest of 9
ROIC minus cost of capital+9.6 pp-11.0 pphighest of 15
EV / EBITDA41.6×13.5×most expensive of 5
Net debt / EBITDA1.4×0.7×2nd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Precigen PGENUnited States$1.53B0%+2,388%21%7.3×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%n/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%n/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%n/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%16.7×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%52.1×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%n/an/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%73.2×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%22.6×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%7.5×-7.6%+33.5%
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%n/an/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%27.6×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a

Questions

Who are Precigen's main competitors?
Named competitors: Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Intellia Therapeutics (NTLA). The cockpit's measured peer set (industry) also includes Kailera Therapeutics (KLRA), Nurix Therapeutics (NRIX), Korsana Biosciences (KRSA), Chengdu Olymvax Biopharmaceuticals (688319.SS), TLC BioSciences (7924.TWO), Vir Biotechnology (VIR).
Is Precigen expensive compared with its peers?
On forward p/e it trades at 7.3× against a peer median of 37.0×, cheapest of 9 in its peer set.
How has Precigen stock performed?
Over six months to 18 Nov 2026 the shares returned 0.0% against -12.8% for the median peer; over one year -12.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.